The drug rapamycin has beneficial effects in a number of animal models of neurodegeneration and aging including mouse models of Alzheimer's disease. Despite its compelling preclinical record, no clinical trials have tested rapamycin or other mTOR inhibitors in patients with Alzheimer's disease. We argue that such clinical trials should be undertaken.
No takes yet. Share an insight, caveat, or question.
Kaeberlein et al. (2019) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: